Analogue-based Drug Discovery III (eBook, PDF)
Schade – dieser Artikel ist leider ausverkauft. Sobald wir wissen, ob und wann der Artikel wieder verfügbar ist, informieren wir Sie an dieser Stelle.
Analogue-based Drug Discovery III (eBook, PDF)
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually…mehr
- Geräte: PC
- eBook Hilfe
Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and -- together with the previous volumes -- constitutes the first systematic approach to drug analogue development.
Produktdetails
- Produktdetails
- Verlag: Wiley-VCH
- Seitenzahl: 404
- Erscheinungstermin: 14. Februar 2013
- Englisch
- ISBN-13: 9783527651115
- Artikelnr.: 37760426
- Verlag: Wiley-VCH
- Seitenzahl: 404
- Erscheinungstermin: 14. Februar 2013
- Englisch
- ISBN-13: 9783527651115
- Artikelnr.: 37760426
János Fischer is a Senior Research Scientist at Richter Plc., Budapest, Hungary. He received his MSc and PhD degrees in organic chemistry from the Eotvos University of Budapest under Professor A. Kucsman. Between 1976 and 1978, he was a Humboldt Fellow at the University of Bonn under Professor W. Steglich. He has worked at Richter Plc. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest is analogue based drug discovery. He is the author of some 100 patents and scientific publications. In 2004, he was elected as a Titular member of the Chemistry and Human Health Division of IUPAC. He received an honorary professorship at the Technical University of Budapest. C. Robin Ganellin studied Chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the co inventors of the revolutionary drug, cimetidine (also known as Tagamet). In 1986, he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Professor Emeritus of Medicinal Chemistry. Professor Ganellin is co inventor of over 160 patents and has authored over 260 scientific publications. He was President of the Medicinal Chemistry Section of the IUPAC and is Chairman of the IUPAC Subcommittee on Medicinal Chemistry and Drug Development. David Rotella is the Margaret and Herman Sokol Professor of Medicinal Chemistry at Montclair State University. He earned a B.S. Pharm. degree at the University of Pittsburgh (1981) and a Ph.D. (1985) at The Ohio State University with Donald. T. Witiak. After postdoctoral studies in organic chemistry at Penn State University with Ken S. Feldman, he was an assistant professor at the University of Mississippi. David worked at Cephalon, Bristol-Myers, Lexicon and Wyeth where he was involved in neurodegeneration, schizophrenia, cardiovascular and metabolic disease drug discovery projects.
PREFACE PART I: General Aspects PIONEER AND ANALOGUE DRUGS Monotarget Drugs Dual-Acting Drugs Multitarget Drugs Summary COMPETITION IN THE PHARMACEUTICAL DRUG DEVELOPMENT Introduction Analogue-Based Drugs: Just Copies? How Often Does Analogue-Based Activity Occur? Insights from the GPCR Patent Space METABOLIC STABILITY AND ANALOGUE-BASED DRUG DISCOVERY Introduction Metabolism-Guided Drug Design Indirect Modulation of Metabolism by Fluorine Substitution Modulation of Low Clearance/Long Half-Life via Metabolism-Guided Design Tactics to Resolve Metabolism Liabilities Due to Non-CYP Enzymes Eliminating RM Liabilities in Drug Design Eliminating Metabolism-Dependent Mutagenicity Eliminating Mechanism-Based Inactivation of CYP Enzymes Identification (and Elimination) of Electrophilic Lead Chemical Matter Mitigating Risks of Idiosyncratic Toxicity via Elimination of RM Formation Case Studies on Elimination of RM Liability in Drug Discovery Concluding Remarks USE OF MACROCYCLES IN DRUG DESIGN EXEMPLIFIED WITH ULIMORELIN, A POTENTIAL GHRELIN AGONIST FOR GASTROINTESTINAL MOTILITY DISORDERS Introduction High-Throughput Screening Results and Hit Selection Macrocycle Structure - Activity Relationships PK - ADME Considerations Structural Studies Preclinical Evaluation Clinical Results and Current Status Summary PART II: Drug Classes THE DISCOVERY OF ANTICANCER DRUGS TARGETING EPIGENETIC ENZYMES Epigenetics DNA Methyltransferases 5-Azacytidine (Azacitidine, Vidaza) and 5-Aza-20-deoxycytidine (Decitabine, Dacogen) Other Nucleoside DNMT Inhibitors Preclinical Zinc-Dependent Histone Deacetylases Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat, Zolinza) FK228 (Depsipeptide, Romidepsin, Istodax) Carboxylic Acid and Benzamide HDAC Inhibitors Prospects for HDAC Inhibitors Epigenetic Drugs - A Slow Start but a Bright Future THIENOPYRIDYL AND DIRECT-ACTING P2Y12 RECEPTOR ANTAGONIST ANTIPLATELET DRUGS Introduction Thienopyridines Direct-Acting P2Y12 Antagonists cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol Summary SELECTIVE ESTROGEN RECEPTOR MODULATORS Introduction Tamoxifen Raloxifene Summary DISCOVERY OF NONPEPTIDE VASOPRESSIN V2 RECEPTOR ANTAGONISTS Introduction Peptide AVP Agonists and Antagonists Lead Generation Strategies Lead Generation Strategy-2, V2 Receptor Affinity Lead Optimization Reported Nonpeptide Vasopressin V2 Receptor Antagonist Compounds Conclusions THE DEVELOPMENT OF CYSTEINYL LEUKOTRIENE RECEPTOR ANTAGONISTS Introduction Scope of the Drug Discovery Effort on Leukotriene Modulators Synthetic Leukotriene Production and Benefits Derived from this Effort Bioassays and General Drug Discovery Testing Cascade Development of Antagonists - General Approaches Discovery of Zafirlukast Discovery of Montelukast Discovery of Pranlukast Comparative Analysis and Crossover Impact Postmarketing Issues Conclusions PART III: Case Studies THE DISCOVERY OF DABIGATRAN ETEXILATE Introduction Dabigatran Design Story Preclinical Pharmacology Molecular Mechanism of Action of Dabigatran Clinical Studies and Indications Summary THE DISCOVERY OF CITALOPRAM AND ITS REFINEMENT TO ESCITALOPRAM Introduction Discovery of Talopram Discovery of Citalopram Synthesis and Production of Citalopram The Pharmacological Profile of Citalopram Clinical Efficacy of Citalopram Synthesis and Production of Escitalopram The Pharmacological Profile of the Citalopram Enantiomers R-Citalopram's Surprising Inhibition of Escitalopram Binding Site(s) for Escitalopram on the Serotonin Transporter Future Perspectives on the Molecular Basis for Escitalopram?s Interaction with the SERT Clinical Efficacy of Escitalopram Conclusions TAPENTADOL - FROM MORPHINE AND TRAMADOL TO THE DISCOVERY OF TAPENTADOL Introduction The Discovery of Tapentadol The Preclinical and Clinical Profile of Tapentadol Summary NOVEL TAXANES: CABAZITA
PREFACE PART I: General Aspects PIONEER AND ANALOGUE DRUGS Monotarget Drugs Dual-Acting Drugs Multitarget Drugs Summary COMPETITION IN THE PHARMACEUTICAL DRUG DEVELOPMENT Introduction Analogue-Based Drugs: Just Copies? How Often Does Analogue-Based Activity Occur? Insights from the GPCR Patent Space METABOLIC STABILITY AND ANALOGUE-BASED DRUG DISCOVERY Introduction Metabolism-Guided Drug Design Indirect Modulation of Metabolism by Fluorine Substitution Modulation of Low Clearance/Long Half-Life via Metabolism-Guided Design Tactics to Resolve Metabolism Liabilities Due to Non-CYP Enzymes Eliminating RM Liabilities in Drug Design Eliminating Metabolism-Dependent Mutagenicity Eliminating Mechanism-Based Inactivation of CYP Enzymes Identification (and Elimination) of Electrophilic Lead Chemical Matter Mitigating Risks of Idiosyncratic Toxicity via Elimination of RM Formation Case Studies on Elimination of RM Liability in Drug Discovery Concluding Remarks USE OF MACROCYCLES IN DRUG DESIGN EXEMPLIFIED WITH ULIMORELIN, A POTENTIAL GHRELIN AGONIST FOR GASTROINTESTINAL MOTILITY DISORDERS Introduction High-Throughput Screening Results and Hit Selection Macrocycle Structure - Activity Relationships PK - ADME Considerations Structural Studies Preclinical Evaluation Clinical Results and Current Status Summary PART II: Drug Classes THE DISCOVERY OF ANTICANCER DRUGS TARGETING EPIGENETIC ENZYMES Epigenetics DNA Methyltransferases 5-Azacytidine (Azacitidine, Vidaza) and 5-Aza-20-deoxycytidine (Decitabine, Dacogen) Other Nucleoside DNMT Inhibitors Preclinical Zinc-Dependent Histone Deacetylases Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat, Zolinza) FK228 (Depsipeptide, Romidepsin, Istodax) Carboxylic Acid and Benzamide HDAC Inhibitors Prospects for HDAC Inhibitors Epigenetic Drugs - A Slow Start but a Bright Future THIENOPYRIDYL AND DIRECT-ACTING P2Y12 RECEPTOR ANTAGONIST ANTIPLATELET DRUGS Introduction Thienopyridines Direct-Acting P2Y12 Antagonists cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol Summary SELECTIVE ESTROGEN RECEPTOR MODULATORS Introduction Tamoxifen Raloxifene Summary DISCOVERY OF NONPEPTIDE VASOPRESSIN V2 RECEPTOR ANTAGONISTS Introduction Peptide AVP Agonists and Antagonists Lead Generation Strategies Lead Generation Strategy-2, V2 Receptor Affinity Lead Optimization Reported Nonpeptide Vasopressin V2 Receptor Antagonist Compounds Conclusions THE DEVELOPMENT OF CYSTEINYL LEUKOTRIENE RECEPTOR ANTAGONISTS Introduction Scope of the Drug Discovery Effort on Leukotriene Modulators Synthetic Leukotriene Production and Benefits Derived from this Effort Bioassays and General Drug Discovery Testing Cascade Development of Antagonists - General Approaches Discovery of Zafirlukast Discovery of Montelukast Discovery of Pranlukast Comparative Analysis and Crossover Impact Postmarketing Issues Conclusions PART III: Case Studies THE DISCOVERY OF DABIGATRAN ETEXILATE Introduction Dabigatran Design Story Preclinical Pharmacology Molecular Mechanism of Action of Dabigatran Clinical Studies and Indications Summary THE DISCOVERY OF CITALOPRAM AND ITS REFINEMENT TO ESCITALOPRAM Introduction Discovery of Talopram Discovery of Citalopram Synthesis and Production of Citalopram The Pharmacological Profile of Citalopram Clinical Efficacy of Citalopram Synthesis and Production of Escitalopram The Pharmacological Profile of the Citalopram Enantiomers R-Citalopram's Surprising Inhibition of Escitalopram Binding Site(s) for Escitalopram on the Serotonin Transporter Future Perspectives on the Molecular Basis for Escitalopram?s Interaction with the SERT Clinical Efficacy of Escitalopram Conclusions TAPENTADOL - FROM MORPHINE AND TRAMADOL TO THE DISCOVERY OF TAPENTADOL Introduction The Discovery of Tapentadol The Preclinical and Clinical Profile of Tapentadol Summary NOVEL TAXANES: CABAZITA